On Friday, Akebia Therapeutics Inc (NASDAQ: AKBA) was 0.66% up from the session before settling in for the closing price of $3.01. A 52-week range for AKBA has been $0.80 – $3.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -13.72% over the past five years. When this article was written, the company’s average yearly earnings per share was at 68.48%. With a float of $251.86 million, this company’s outstanding shares have now reached $261.64 million.
Let’s look at the performance matrix of the company that is accounted for 181 employees. In terms of profitability, gross margin is 67.77%, operating margin of -11.91%, and the pretax margin is -24.51%.
Akebia Therapeutics Inc (AKBA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Akebia Therapeutics Inc stocks. The insider ownership of Akebia Therapeutics Inc is 4.10%, while institutional ownership is 36.60%. The most recent insider transaction that took place on Mar 03 ’25, was worth 84,928. In this transaction CEO and President of this company sold 46,409 shares at a rate of $1.83, taking the stock ownership to the 2,557,921 shares. Before that another transaction happened on Mar 03 ’25, when Company’s SVP, Chief Medical Officer sold 7,144 for $1.83, making the entire transaction worth $13,074. This insider now owns 809,090 shares in total.
Akebia Therapeutics Inc (AKBA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 68.48% per share during the next fiscal year.
Akebia Therapeutics Inc (NASDAQ: AKBA) Trading Performance Indicators
You can see what Akebia Therapeutics Inc (AKBA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.22, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.02 in one year’s time.
Technical Analysis of Akebia Therapeutics Inc (AKBA)
Akebia Therapeutics Inc (NASDAQ: AKBA) saw its 5-day average volume 5.02 million, a positive change from its year-to-date volume of 3.89 million. As of the previous 9 days, the stock’s Stochastic %D was 80.48%. Additionally, its Average True Range was 0.15.
During the past 100 days, Akebia Therapeutics Inc’s (AKBA) raw stochastic average was set at 93.21%, which indicates a significant increase from 86.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.13% in the past 14 days, which was lower than the 94.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.27, while its 200-day Moving Average is $1.90. Nevertheless, the first resistance level for the watch stands at $3.07 in the near term. At $3.11, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.16. If the price goes on to break the first support level at $2.98, it is likely to go to the next support level at $2.93. The third support level lies at $2.89 if the price breaches the second support level.
Akebia Therapeutics Inc (NASDAQ: AKBA) Key Stats
There are 262,636K outstanding shares of the company, which has a market capitalization of 795.79 million. As of now, sales total 160,180 K while income totals -69,410 K. Its latest quarter income was 57,340 K while its last quarter net income were 6,110 K.
